Cargando…

Two Types of Immune Checkpoint Inhibitor-related Pancreatitis

Detalles Bibliográficos
Autores principales:	Ichiki, Tomoko, Hori, Yasuki, Tsuji, Yoshihisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177351/ https://www.ncbi.nlm.nih.gov/pubmed/34744111 http://dx.doi.org/10.2169/internalmedicine.8452-21

Ejemplares similares

Fatal Immune Checkpoint Inhibitor-related Pancreatitis
por: Ueno, Masayuki, et al.
Publicado: (2021)

The prospect of combination therapy with immune checkpoint inhibitors and chemotherapy for squamous cell carcinoma of the lung
por: Ichiki, Yoshinobu, et al.
Publicado: (2020)

Equibalancing immune‐related adverse events and anticancer activity of immune checkpoint inhibitors
por: Seeruttun, Sharvesh Raj
Publicado: (2019)

Immune checkpoint inhibitors in penile cancer
por: Buonerba, Carlo, et al.
Publicado: (2021)

Cardiotoxicity Associated with Immune Checkpoint Inhibitors
por: Minegishi, Shintaro, et al.
Publicado: (2023)

Natriuretic Peptide-Based Novel Therapeutics: Long Journeys of Drug Developments Optimized for Disease States
por: Ichiki, Tomoko, et al.
Publicado: (2022)

Immune checkpoint inhibitor-related pancreatitis: What is known and what is not
por: Jiang, Chunyan, et al.
Publicado: (2023)

Evolving cardiac biomarkers for immune checkpoint inhibitor related myocarditis in cancer patients
por: Talukder, Suprateeka, et al.
Publicado: (2023)

Immune checkpoint inhibitors in renal cell carcinoma
por: Ross, Kirsty, et al.
Publicado: (2017)

Advanced Research on Immune Checkpoint Inhibitor Therapy
por: Imai, Hisao, et al.
Publicado: (2022)

Immune checkpoint inhibitors: here to stay
por: Carvalho, Filomena Marino, et al.
Publicado: (2023)

The neurotoxic effects of immune checkpoint inhibitor therapy for melanoma
por: Spain, Lavinia, et al.
Publicado: (2019)

Two types of fulminant type 1 diabetes mellitus: Immune checkpoint inhibitor‐related and conventional
por: Imagawa, Akihisa
Publicado: (2020)

Immune Checkpoints Contribute Corneal Immune Privilege: Implications for Dry Eye Associated with Checkpoint Inhibitors
por: Hori, Junko, et al.
Publicado: (2020)

Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors
por: Wang, Zheng-Hang, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in Uro-Oncology: Urgent Call for Biomarkers
por: Pichler, Renate
Publicado: (2020)

Unlocking the Potential of Biomarkers for Immune Checkpoint Inhibitors in Cancer Therapy
por: Dal Collo, Giada, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-Induced Acute Pancreatitis and Colitis
por: Pagan, Andrea, et al.
Publicado: (2020)

Assessment of soluble immune mediators as potential biomarkers during immune checkpoint inhibitor therapy
por: Matsuo, Norikazu, et al.
Publicado: (2019)

Immune checkpoint inhibitors-related pancreatitis with fulminant type 1 diabetes mellitus: case report and literature review
por: Fang, Wei, et al.
Publicado: (2023)

Repurposing glucocorticoids as adjuvant reagents for immune checkpoint inhibitors in solid cancers
por: Yu, Yingyan
Publicado: (2021)

The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?
por: Cummings, Amy L., et al.
Publicado: (2017)

A Lack of Biomarkers for Cardiac Complications of Immune Checkpoint Inhibitor Therapy
por: Li, Siqi, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor-related Endocrinopathies
por: Lu, Difei, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors Related to Cardiotoxicity
por: Chen, Ru, et al.
Publicado: (2022)

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
por: Kasparian, Saro, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor Therapy: A Boon to Elderly Patients with Advanced Melanoma?
por: Muta, Tsuyoshi
Publicado: (2018)

Evaluation of response to immune checkpoint inhibitors: Is there a role for positron emission tomography?
por: Bauckneht, Matteo, et al.
Publicado: (2017)

Immune Checkpoint Inhibitors in the Pre-operative Setting and Impact on the Primary Renal Tumor
por: Gulati, Shuchi, et al.
Publicado: (2022)

Biomarkers for immune checkpoint inhibitors in colorectal cancer: recent advances and future perspectives
por: Yang, Changjiang, et al.
Publicado: (2023)

Coexistence of Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes and Pancreatitis
por: Zhang, Amy L., et al.
Publicado: (2021)

Pancreatic adverse events in patients treated with immune checkpoint inhibitors
por: Hana, Caroline, et al.
Publicado: (2023)

Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma
por: Akhuba, Liia, et al.
Publicado: (2023)

Immune checkpoint inhibitor in liver cancer—unique regional differences
por: Obi, Shuntaro, et al.
Publicado: (2020)

Immune checkpoint inhibitors: Advances and impact in neuro-oncology
por: Fares, Jawad, et al.
Publicado: (2019)

Cancer vaccines: the importance of targeting oncogenic drivers and the utility of combinations with immune checkpoint inhibitors
por: Crosby, Erika J., et al.
Publicado: (2021)

Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…
por: Thungappa, Satheesh, et al.
Publicado: (2017)

Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?
por: Gravara, Luigi Della, et al.
Publicado: (2020)

Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?
por: Niegisch, Günter
Publicado: (2019)

A Diverse Range of Cardiac Adverse Events Associated with Immune Checkpoint Inhibitor Therapy
por: Murakata, Yoshiko, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b6psckd6ol9tu50ceik24jbnfl